Clinical trial · Interventional
Study to Investigate Bronchial Arterrial Infusing (BAI) Plus Three-dimensional Conformal Radiotherapy (3DCRT) in Local Advanced Non-small Cell Lung Cancer (NSCLC)
A Randomized, Two Arm Study to Investigate Bronchial Arterrial Infusing (BAI) Plus Three-dimensional Conformal Radiotherapy (3DCRT) in Local Advanced Non-small Cell Lung Cancer (NSCLC)
NCT01201044CI-TRIAL-00003904DO201001unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to investigate the efficacy of BAI Plus 3DCRT in local advanced NSCLC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 3DCRT | Radiation | — | UNRESOLVED |
| Gemcitabine，Nedaplatin, BAI | Drug | — | UNRESOLVED |
| Gemcitabine, Nedaplatin, iV | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Gemcitabine, Nedaplatin,BAI plus 3DCRT
- description
- Gemcitabine(1000mg/m2)，Nedaplatin(60mg/m2),BAI, Day 1/4weeks. 4weeks per cycle. Tumor assessment will be perforemd after 2 cycles. if no PD, patient will be treated with 3DCRTfor 1 month. for patient PD after 3DCRT, complete the study. patient no PD after 3DCRT will receive 2 cycle of chemo with Gemcitabine. Nedaplatin. then patient will be followed for 1 year..
- interventionNames
- Radiation: 3DCRT
- Drug: Gemcitabine，Nedaplatin, BAI
- type
- OTHER
- label
- Gemcitabine, Nedaplatin, IV Plus 3DCRT
- description
- Gemcitabine 100mg/m2, D1 \& D8 every 4 weeks Nedaplatin 75mg/m2, D1 every 4 weeks. every 4 weeks per cycle. Tumor assessment will be performed after 2 cycles. if no PD, patient will be treated with 3DCRT for 1 month. for patient PD after 3DCRT, complete the study. patient no PD after 3DCRT will receive 2 cycle of chemo with Gemcitabine. Nedaplatin. then patient will be followed for 1 year.
- interventionNames
- Drug: Gemcitabine, Nedaplatin, iV
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * stage IIIA\&IIIB NSCLC * male or female, Age ≥18Years, ≤70Years * Life expectation of at least 12weeks. * PS performance 0-2 * Measurable disease according to the Response Evaluation Criteria in Solid Tumours ( RECIST) Exclusion Criteria: * Patient with prior chemotherapy or radiology for IIIA or IIIB NSCLC
References
Publications (0)
Data not yet available
No reference posted for this study.